MedInnovate Limited is registered in England & Wales No. 05318138 © MedInnovate 2011
Creating, developing and transforming life science businesses
Maureen Coleman
Maureen Coleman graduated in Pharmacy from Strathclyde University in 1974, completed her training in the Ashington District Hospitals then joined Sterling Winthrop R&D as laboratory leader. After a short time in the NHS as staff pharmacist and Chair of the Hillingdon Area Health Authority Pharmacy Committee she joined Glaxo in 1978 where she remained for over 25 years in positions of increasing responsibility. Roles included Unit head for pharmaceutical formulation, founding head of the Product Evaluation Department responsible for stability policy and testing of all Glaxo R&D products, International Project Leader for major NCE, VP International Clinical Supplies, VP Strategy & Business Operations for Global Pharmaceutical Development, and VP Global R&D Strategy Development for GSK post-
In 2007, with Professor Dame Julia Polak and Professor Larry Hench she founded NovaThera a regenerative medicine and biomaterials company as a spinout from Imperial College London where as CEO she developed the company strategy, raised finance and established a high quality board before recruiting her successor.
Maureen is currently Executive Chairman of both Parafricta and Zyoxel. Under her chairmanship Parafricta secured registration and reimbursement listing in the UK for their range of medical devices, has published a study proving both clinical and cost effectiveness and has secured on-going funding to support the commercialisation, sales and marketing of the products.
Zyoxel, a spin out from the University of Oxford, has secured second round funding to support the ongoing development and commercialisation of its proprietary 3d perfused cell culture systems (Tissuflex) and to develop its commercial arrangements with both Oxford University and MIT.
Maureen has held a number of other Non-Executive board positions including with GlaxoWelcome Moroc & Medpharm Ltd. She has been an investor in and supporter of several life science start-up businesses, providing advice and support to the leadership of each business. This has included BioAnalab which was sold to Merck Millipore. She has worked with the technology transfer & SME management groups of Oxford University, Imperial College, Kings College, and Brunel Universities. Recently she mentored and advised the board of the Academy of Pharmaceutical Sciences as it refreshed its mission and aims, establishing itself as the leading organisation representing the pharmaceutical sciences in the UK.
Maureen has undertaken a number of consulting assignments with MedInnovate and as a business partner with Kinapse Ltd where she was instrumental in the establishment of a CMC support business in UK, US, and India. Assignments have varied widely including
|
○
|
Developing a proposal for the Scottish Government to establish a commercially viable national bio-
|
|
○
|
Defining the strategy to provide clinical supplies service for a large rapidly growing Contract Research Organisation
|
|
○
|
Organisational design and strategic direction for regulatory, quality and development organisations of three top 20 global pharma/biotech companies (US, Europe & Japan)
|
|
○
|
Defining the way forward for a stalled initiative to provide a globally competitive, clinical trial service across the leading universities and hospitals in London.
|
Maureen represented the pharmaceutical industry during the derivation of the ICH Quality Guidelines and was instrumental in defining the first ICH stability testing guidelines. She was a member of the British Technology Strategy Forum. She is married with has two grown-up children, is a keen cyclist, “Gooner”, and enjoys all aspects of cooking, eating, drinking and being merry.